NewEdge Advisors’s Alaunos Therapeutics TCRT Stock Holding History

NewEdge Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4	Closed	-$357	–	4091
2022 Q4	$357	Buy	+4	New	+$580	﹤0.01%	3226

Other funds holding TCRT

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

NewEdge Advisors's TCRT Position: Q1 2023 in Review

NewEdge Advisors sold out of Alaunos Therapeutics (TCRT) in Q1 2023, closing a stake of 4 shares — an estimated $357 sold.

NewEdge Advisors first reported a position in TCRT in Q4 2022 and held it in 1 quarter. The position peaked at $357 in Q4 2022. 108 funds tracked by Wall St. Rank hold TCRT as of Q1 2023.

NewEdge Advisors reported no remaining Alaunos Therapeutics position as of Q1 2023 after selling out during the quarter.
NewEdge Advisors sold 4 Alaunos Therapeutics shares in Q1 2023, an estimated $357.
NewEdge Advisors first reported a position in Alaunos Therapeutics in Q4 2022 and held it in 1 quarter.
NewEdge Advisors's Alaunos Therapeutics position peaked at $357 in Q4 2022.
108 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.